Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19844159 | 0.92 | GPR119 (0.78) | GPR119 | |
| SCHEMBL11885633 | 0.92 | GPR119 (0.78) | GPR119 | |
| SCHEMBL3487527 | 0.92 | GPR119 (0.78) | GPR119 | |
| SCHEMBL1118409 | 0.89 | GPR119 (0.83) | GPR119KCNJ1 | |
| SCHEMBL8022934 | 0.84 | GPR119 (0.65) | GPR119 | |
| SCHEMBL1118305 | 0.84 | GPR119 (0.65) | GPR119 | |
| SCHEMBL1118200 | 0.82 | GPR119 (0.91) | GPR119 | |
| SCHEMBL1118607 | 0.81 | GPR119 (0.71) | GPR119KCNJ1 | |
| Mbx-2982 SCHEMBL1118326 | 0.80 | GPR119 (1.00) | GPR119 | |
| SCHEMBL3685203 | 0.79 | GPR119 (0.49) | GPR119KCNJ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281691-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | CYMABAY THERAPEUTICS, INC. | 2013-10-24 | — | — | US | disclosed |
| US-20130281691-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | CYMABAY THERAPEUTICS, INC. | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281691-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, INSR, GLP1R | GPR119 1/4885KCNJ1 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.